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Initially correlated with hematopoietic precursors, the surface expression of CD133 was also found in epithelial and nonepithelial
cells from adult tissues in which it has been associated with a number of biological events. CD133 is expressed in solid tumors as
well, including breast cancer, in whichmost of the studies have been focused on its use as a surface marker for the detection of cells
with stem-like properties (i.e., cancer stem cells (CSCs)). Differently with other solid tumors, very limited and in part controversial
are the information about the significance of CD133 in breast cancer, the most common malignancy among women in in-
dustrialized countries. In this review, we summarize the latest findings about the implication of CD133 in breast tumors,
highlighting its role in tumor cells with a triple negative phenotype in which it directly regulates the expression of proteins
involved in metastasis and drug resistance. We provide updates about the prognostic role of CD133, underlining its value as an
indicator of increased malignancy of both noninvasive and invasive breast tumor cells. )e molecular mechanisms at the basis of
the regulation of CD133 levels in breast tumors have also been reviewed, highlighting experimental strategies capable to restrain
its level that could be taken into account to reduce malignancy and/or to prevent the progression of breast tumors.
1. Introduction
CD133/prominin 1 (PROM1) is a pentaspan trans-
membrane single-chain glycoprotein (Figure 1(a)) mainly
localized into protrusions of cellular plasma membrane and
particularly in the cholesterol-based lipid microdomains,
indicative of its involvement in membrane organization [1].
Transcription of human CD133 is driven by five tissue-
specific promoters, three of which located in CpG islands
and partially regulated by methylation (Figure 1(b)), leading
to spliced mRNAs which results in CD133 isoforms with
possibly distinct roles [2].
CD133 was firstly revealed as the target of a monoclonal
antibody directed against the AC133 epitope expressed by a
subpopulation of CD34+ hematopoietic stem cells from the
human fetal liver and bone marrow [3]. Despite the initial
correlation of CD133 expression with progenitor cells [4, 5],
accumulating evidence demonstrated that this surface
antigen also characterizes adult tissues, including mammary
gland [6–10]. In normal breast tissue, CD133 is not a stem
cell marker and plays a role in morphogenesis, regulating
ductal branching and the ratio of luminal to basal cells [10].
Even though CD133 has been variously associated with
proliferation, cell survival, and autophagy, in precursors
and/or mature cells [11], its exact role is not well defined and
a specific ligand was not discovered.
)e expression of CD133 is deregulated in various solid
tumors; however, despite numerous studies, the role of this
surface antigen in tumorigenesis and tumor progression is
largely unknown [12]. In particular, it is not clear, and in part
controversial, the role of CD133 in breast tumors, the most
common malignancy and the second cause of cancer-related
death among women in industrialized countries. )e aim of
this review is to summarize the latest findings about the
meaning of CD133 in breast cancer, focusing on its re-
lationship with the malignant evolution of the neoplasia.
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2. CD133 as a Cancer Stem Cell Marker
Most of the studies in solid tumors have been focused on its
use as a surface marker for the detection of cells with stem-
like properties (i.e., cancer stem cells (CSCs)) [2, 13]. Due to
its more restricted expression compared with other CSC
markers such as CD44 and aldehyde dehydrogenase
(ALDH), CD133 has long been considered the most rigorous
indicator of malignant precursors in different solid tumors,
including breast cancer [14].
In breast tumors, the role of CD133 as a CSCmarker was
firstly demonstrated in cell lines derived from BRCA1-as-
sociated murine mammary tumors, in which CD133+ cells
were shown to have a greater colony-forming efficiency,
higher proliferative rate, and greater capability to form
tumors in NOD/SCID mice [15]. In human invasive breast
cancer cell lines, Croker et al. [16] firstly identified sub-
populations of cells expressing CD133 together with the
putative CSC markers CD44/CD24 and ALDH. When
isolated by fluorescence-activated cell sorting and subjected
to functional assays, these subpopulations showed increased
growth, colony formation ability, migration, invasion, and
induced tumorigenesis and metastasis in mice. In particular,
ALDHhighCD44+CD133+ cells isolated from MDA-MB-231
and MDA-MB-468 cell lines, displaying a triple negative
phenotype (ER-, PR-, and HER2-), showed enhanced ma-
lignant/metastatic behavior both in vitro and in vivo [16].
Furthermore, a subpopulation of CD44+CD49highCD133/
2high cells isolated from ER-negative tumors was demon-
strated to be enriched for xenograft-initiating cells capable of
giving rise to triple negative and ER-negative/HER2-positive
tumors [17], endorsing CD133 as a suitable molecule for the
identification of CSCs in the most aggressive subtypes of
breast cancer. Indeed, when the expression of CD133 was
evaluated in breast tumor cell lines with different pheno-
types, a strong variability was found. In fact, the number of
CD133+ cells ranged between 1 and 10% in claudin-low cells,
reached 80% in basal-like cell lines, and were between 1 and
2% in both luminal and HER2+ cells, questioning the
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Figure 1: Structure and regulation of CD133. (a) CD133 protein structure in which the C-terminal tyrosine-phosphorylation consensus site,
which comprises 5 tyrosine residues including Y828 and Y852, and the splice variants regions are indicated. (b) Schematic representation of
the 5′ untranslated region of the CD133 gene. Transcription factors that positively (green circles) or negatively (red circles) regulate CD133
expression by direct binding to the different promoters are reported. )e direct binding of Notch1 to the site for RBP-Jk located upstream
P1–P5 promoters is also indicated.
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in breast tumor cells [18]. For this reason, although also
recently it was used as the sole marker of CSCs [19], CD133
belongs to a well-known panel of molecules that, when
properly combined, can actually identify cells with a stem-
like phenotype in breast cancer cell lines and primary tumors
with different phenotypes [13, 20].
3. CD133 as a Prognostic Marker
Although the data concerning the use of the only CD133 to
identify CSCs are contradictory, the majority of the studies
so far report for CD133 a significant predictive value [21].
Anyway, since CSCs generally express CD133, the prog-
nostic significance of this surface antigen is generally cor-
related with the stem-like properties of CD133+ cells [13].
)e role for CD133 as a prognostic marker in breast
cancer was firstly demonstrated by Liu et al., who revealed
that high PROM1 expression in invasive ductal carcinoma
positively correlates with adverse clinic-pathological factors,
as tumor size and lymph node metastasis [22]. More re-
cently, it was demonstrated that both CD133 mRNA and
protein expression are important biomarkers for prognosis
as they positively correlate with higher tumor grade, oc-
currence of lymph node metastasis, negative PR and ER and
positive HER2 status, advanced TNM stage, and poor overall
survival (OS) [23–25]. While both cytoplasmic and mem-
brane CD133 were linked to shorter survival, membrane
positivity only seems to confer the worst patient outcome.
Furthermore, high membrane expression of CD133 was
significantly associated with younger age at diagnosis and
premenopausal status [26].
Despite the general relationship between CD133 and
breast tumor malignancy, some controversies concern the
significance of CD133 in tumors with a triple negative
phenotype (TNBC), in which CD133 is strongly hypo-
methylated with respect to other breast cancer subtypes
[27]. A strong negative correlation of CD133 levels with
clinical stage of TNBC tumors was firstly observed by Zhao
et al. [28], and the use of CD133 to detect circulating tumor
cells in TNBC patients ratified its role in prognosis of this
breast cancer subtype [29]. Still in TNBC, Cantile et al.
suggested that poor prognosis is possibly due to a nuclear
mislocalization of CD133, which normally shows a
membrane, and more sporadically cytoplasmic, localiza-
tion [30]. In contrast to all the previous experimental
evidences, Collina et al., who described a prevalent cyto-
plasmic expression of CD133, failed to reveal statistical
association of CD133 expression with TNBCs patients’
survival [31]. )is discordance may be at least in part
ascribed to the well-known problem that concerns the
different antibodies used to detect CD133 by cytofluori-
metrical and immunohistochemical investigations [21], as
well as to the absence of standardized criteria to define the
scores used for the quantification of the glycoprotein at
membrane, cytoplasm, and nuclear level.
A recent study performed with the Gene Expression-
Based Outcome for Breast Cancer Online (GOBO) algo-
rithm confirmed that CD133 mRNA is associated with
distant metastasis-free survival (DMFS) in patients with all
the subtypes of breast cancer [24]. More recently, the
overexpression of both CD133 mRNA and protein were
investigated in large well-characterized BC cohorts, resulting
particularly high in TNBC and HER2+ tumors and con-
firming the negative prognostic value of CD133 in all breast
tumor subtypes [26].
In breast cancer, CD133 is also useful in predicting
chemosensitivity to neoadjuvant chemotherapy (NAC) [32].
Interestingly, the treatment with NAC resulted in the en-
richment of CD133+ cells and in the positive correlation of
the surface antigen with prognosis, contrarily to its negative
significance in pre-NAC tumors [32]. )e potential role of
CD133 as a marker of chemoresistance in nonluminal breast
cancer subtypes was also proposed, on the basis of the
relative enrichment of CSCs expressing the surface antigen
after systemic therapy [29].
3.1. CD133 Regulates Invasive Potential of TNBC-Derived
Cells. Various signaling pathways, all directly involved in
the acquisition of malignant properties, have been correlated
with CD133 levels in solid tumors, supporting its role in
different stages of cancer development, including initiation,
progression, and metastasis [12]. )e identification of
CD133 as a substrate for Src and Fyn families of tyrosine
kinases suggests that its cytoplasmic domain could play an
important role in the regulation of its functions
(Figure 1(a)). In particular, the phosphorylation of tyrosine-
828 and tyrosine-852 may regulate interaction of CD133
with SH2-domain containing proteins, which may be in-
volved in a number of intracellular signaling events [33],
including the activation of PI3K/Akt pathway [34–37].
At variance with other solid tumors, little is known about
the signaling associated to CD133 in breast cancer cells
(Figure 2). Interestingly, the almost totality of the data on
breast tumors correlate CD133 with molecules involved in
cell motility and invasion, suggesting a direct role of PROM1
in modulating the potential malignancy of breast tumors. A
role of CD133 in regulating the migration rate of breast
cancer cells was firstly revealed in a murine model and
involved c-Met and STAT3, both downstream to the Wnt
signaling and responsible of cancer invasion and metastasis
[38]. A peculiar role of CD133 in the direct modulation of
motility and invasive potential of breast tumor cells was
demonstrated in the TNBC-derived MDA-MB-231 cell line
that comprises a small cellular subset expressing high levels
of CD133 at both membrane and cytoplasm levels. Re-
markably, the CD133 high cells showed lower proliferation
[39], in accordance with the evidence of Di Bonito et al.,
indicating that only in TNBC, both CD133 mRNA and
protein positively correlate with geminin, an inhibitor of cell
cycle progression [40]. CD133 high cells also showed a larger
adhesion area, consistent with a more differentiated phe-
notype [39], according to the described role of CD133 in
regulating differentiation of normal mammary gland [10].
On the other hand, CD133 high cells exhibited greater in-
vasion capability, suggestive of higher metastatic potential,
in accordance with the positive correlation between CD133
and poor prognosis in breast cancer. At variance with other
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studies, these data highlight the value of both the number of
CD133+ cells and the expression levels of the surface antigen,
which at least in part may justify some discrepancies on the
described prognostic role of CD133 in breast tumors.
When MDA-MB-231 subpopulations expressing dif-
ferent levels of CD133 were subjected to two-dimensional
electrophoresis followed by mass spectrometry, specific
protein signatures were found, including proteins known to
be deregulated and to play crucial roles in breast cancer [39].
As expected, the fastest CD133 low cells expressed lower
levels of proteins involved in cell cycle and apoptosis, and the
most invasive CD133 high cells showed higher expression of
proteins with an oncogenic/metastatic role. )e CD133-
related proteins included the actin-binding protein tropo-
myosin4 (Tm4), upregulated in highly metastatic breast
cancer cell lines and associated with lymph node metastasis
of breast tumors [41] and AdoHcyase (Figure 2), known to
play a key role in the control of DNAmethylation [42] and in
the regulation of cell cycle, apoptosis, and cellular differ-
entiation of breast tumor cells [43]. Of note, the silencing of
CD133 in CD133 high cells reduced invasiveness and ex-
pression of Tm4, ascertaining the existence of direct
mechanisms by which CD133 can promote invasiveness of
TNBC-derived cells [39].
A relationship between CD133 and EMT markers was
demonstrated in tumors cells from metastatic breast cancer
patients. In particular, the concomitant overexpression of
N-cadherin and CD133 was revealed in both circulating
tumor cells [44, 45] and breast cancer specimens [46], even if
a significant correlation between the two molecules and
patient’s prognosis was not fully demonstrated.
4. CD133 as a Marker of Malignant Progression
Induced by Low Oxygen Availability
A crucial driving force in the progression towards a more
aggressive and resistant tumor phenotype is the adaptation
of neoplastic cells to a state of reduced oxygen availability
defined as hypoxia [47–52]. At least half of all solid tumors,
including breast cancer, enclose hypoxic regions varying in
amount and size, and recurring tumors often exhibit a
hypoxic fraction higher than primary tumors [53]. Intra-
tumoral hypoxia has been identified as an adverse prognostic
indicator independent of all the histopathological parame-
ters and, in breast cancer, as in many other solid cancers, low
oxygen availability has been reported as associated with a
clinically aggressive tumor behavior [54].
In solid tumors, including breast cancer, CD133 is
generally induced by low oxygen availability via upregula-
tion HIF-1α (Figures 1(b) and 2), even though only in colon
cancer cells a physical interaction of HIF-1α with the CD133
promoter was demonstrated [55–58]. Once again, the almost
totality of the studies correlating CD133 with low oxygen
availability looked at PROM1 as a marker of CSCs, known to
increase under hypoxia [50].
In breast tumors, Currie et al. firstly associated the ex-
pression of CD133 with markers of hypoxia and/or tumor
microvasculature in invasive and noninvasive breast carci-
noma [23] although most of the further studies correlating
CD133 to low oxygen availability were performed in TNBC.
In MDA-MB-231-derived xenografts, CD133+ cells with
cancer stem cell characteristics were related to vasculogenic
mimicry (VM) (Figure 2) and hypoxia induced by the
antiangiogenic agent sunitinib [59]. In the same cell model,
only CD133+ cells formed VM channels in Matrigel after
reoxygenation, suggesting that hypoxia accelerates VM by
stimulating the CSC population [60]. Again in TNBCs,
chemoresistance was associated with higher numbers of
CD133/ALDH1 or CD133/CD146 coexpressing cells that
were in a quiescent autophagic state related to hypoxia [61].
A further correlation of CD133 with autophagy induced by
low oxygen availability was performed in patient-derived
TNBC xenografts, in which hypoxia increased drug re-
sistance of CD133+ cells, and the inhibition of the auto-
phagic pathway reversed chemoresistance [61].
More recent in vitro studies suggest that the effects of
hypoxia on the expression of CD133 in breast tumor cells are
closely related to their phenotype, and particularly to their
ER status. In fact, low oxygen availability seems to induce
CD133 only in ER+ cells and mostly in cells belonging to the
luminal A subtype [62]. At variance with experiments in
which hypoxia was pharmacologically induced in xenografts
[60], no significant modifications of CD133 were revealed in
TNBC-derived cells cultured under low oxygen [62]. At the
basis of this discrepancy could be the change of the gly-
cosylation status of CD133 induced by hypoxia, in turn
responsible of abnormal detection of the extracellular gly-
cosylated AC133 epitope, as observed in glioma cells [63].
Since hypoxia improves both the number of cells























Figure 2: Regulation and functional roles of CD133 in breast
cancer. Schematic summary of the main mechanisms regulating
CD133 gene expression in breast cancer cells (green circles: positive
regulators; red circles: negative regulators) and of cellular events
directly targeted by CD133 and involved in breast cancer
progression.
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of the noninvasive MCF10DCIS cells [64], the increase of
CD133 was considered a marker of malignant evolution
induced by low oxygen availability in both noninvasive and
low-invasive breast tumors.
5. Regulation of CD133 Levels
)e expression of CD133 is controlled by many extracellular
and intracellular agents, and hypoxic tumor microenvi-
ronment and mitochondria dysfunctions seem to be the
main events modulating CD133 levels [2, 11]. In particular,
hypoxia can improve the levels of the CD133 mRNA by
acting at transcriptional level and can increase the recovery
of the AC133 epitope, by regulating its glycosylation status
[58, 63].
Apart from the hypoxia-related role of HIF-1α, there is a
general agreement that the transcription factors that interact
with CD133 promoters are tumor dependent [12]. For this
reason, although substantial evidence assigns to the increase
of CD133 levels a crucial role in the malignant potential of
various solid tumors, the regulatory mechanisms that pro-
mote CD133 expression are still largely unknown in breast
cancer. )e relationship between CD133+ cancer stem cells
and the Notch signaling was shown in several tumors, in-
cluding breast cancer [65, 66], but only in gastric cancer
cells, the direct binding of Notch 1 with the promoter region
of CD133 was demonstrated [67]. In colon cancer and os-
teosarcoma, CD133 expression is negatively regulated by
direct binding of p53 to a noncanonical p53-binding se-
quence in the CD133 promoter [68]. Moreover, TGFβ1 is
able to regulate CD133 expression in hepatocellular carci-
noma through inhibition of DNMT1 and DNMT3β ex-
pression [69] (Figure 1(b)).
Abnormal DNA methylation, usually reported in many
human cancers, seems to play a critical role in CD133 ex-
pression, and deregulation of the methylation status was
proposed to be at the basis of increased CD133 expression in
breast cancer. In particular, D’Anello and colleagues [70]
reported that IL-6 induced loss of methylation at CD133
promoter enhancing CD133 gene transcription in basal-like
breast cancer via an autocrine loop triggered by the in-
activation of p53. Moreover, in cells with a luminal A
phenotype, but not in TNBC-derived cells, the expression of
CD133 was linked to MALAT1, one of the most widely
studied long coding RNA in cancer development and
progression, and to the RNA binding protein HuR
(Figure 1(b)). HuR/MALAT1 impact on CD133 gene ex-
pression can regulate EMT features, suggesting that the
specific regulation of these molecules could control, at least
in part, the CD133-related tumor progression [71].
5.1. PLC-β2 Regulates CD133 in Breast Cancer Cells. An
unexpected role in the regulation of CD133 mRNA in breast
tumor cells was reported for the beta-2 isoform of PLC
(PLC-β2) (Figure 2), poorly expressed in normal breast
tissues and upregulated in tumor cells, in which sustains
motility of invasive cells [72, 73]. )e first evidence of a
direct regulation of CD133 by PLC-β2 was obtained in
MDA-MB-231 cells, in which overexpression of the PLC
significantly reduced both membrane-associated and cyto-
plasmic levels of CD133, in parallel with the CD133-related
invasion capability [46]. In the same cell model, PLC-β2
regulates the amount of CD133+ cells with stem-like fea-
tures. In particular, overexpression of PLC-β2 reduced the
number of CD44+/CD133+/EpCAM+ cells and proliferation
and invasion capability of the CD133+/EpCAM+ cellular
subset [74].
A role of PLC-β2 in modulating CD133 expression was
also demonstrated in breast tumor derived cells under
hypoxia. In particular, culture at low oxygen availability
reduced PLC-β2 amount and increased CD133 expression in
ER+ breast tumor cells. Counteracting the decrease of PLC-
β2 prevented the increase of CD133 induced by hypoxia and
significantly reduced the hypoxia-related accumulation of
HIF-1α (Figure 2), a putative regulator of CD133 in this cell
model [62].)e same study demonstrated that PLC-β2 is not
modified by hypoxia in TNBC-derived cells, in which low
oxygen availability fails to induce CD133. On the other hand,
its forced expression induced a decrease of the number of
CD133+ cells, confirming, also in this breast tumor subtype,
the role of PLC-β2 in downregulating CD133 [62].
PLC-β2 is ectopically expressed and regulates the
number of cells expressing CD133 also in the noninvasive
MCF10DCIS cells [75]. In the same cell model, the ad-
ministration of all trans retinoic acid (ATRA), currently
used in the management of acute promyelocytic leukemia
[76] in which it induces the expression of PLC-β2 [77],
counteracts the effects of hypoxia on CD133 expression by
up-modulating the PLC isozyme [64]. )ese data constitute
the first evidence that CD133 levels can be modulated by
acting on specific signaling molecules and suggest that ag-
onists able to upmodulate PLC-β2 could counteract the
CD133-related malignant properties in noninvasive and
invasive breast tumor cells.
6. Conclusion
)is review collects the data concerning the expression of
CD133 in breast cancer in which this surface antigen is
generally associated with a stem cell-like phenotype. In
parallel with the role as a cancer stem cell marker, we
reviewed the value of CD133 as a prognostic factor and
indicator of malignant progression of breast tumors,
highlighting its direct role in modulating invasive potential
of breast tumor cells with a triple negative phenotype. We
also revised the mechanisms regulating CD133 gene ex-
pression in both noninvasive and invasive breast tumor cells,
underlining experimental strategies capable to limit its ex-
pression level that could constitute the basis for new ther-
apeutic approaches to reduce malignancy and/or to prevent
progression of breast tumors.
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